PMID- 3896215
OWN - NLM
STAT- MEDLINE
DCOM- 19850925
LR  - 20190824
IS  - 0004-8291 (Print)
IS  - 0004-8291 (Linking)
VI  - 15
IP  - 2
DP  - 1985 Apr
TI  - Insulin secretion and immuno-genetic markers in diabetics with 'secondary 
      failure' of oral hypoglycemic agents.
PG  - 209-12
AB  - 'Secondary failure' of oral hypoglycemics, in non-insulin dependent diabetics, 
      has been attributed to dietary non-compliance, inadequate drug dosage, metabolic 
      stress, or true drug failure. Progressive loss of beta cell function is a 
      suggested mechanism for true drug failure but on the basis of little documented 
      evidence. In view of this, we have measured basal and glucagon-stimulated 
      C-peptide levels, human leukocyte antigen (HLA) types, and islet cell antibodies 
      in 20 non-insulin dependent diabetics with 'secondary failure' of oral agents. 
      There were 16 females and four males with a mean ideal body weight of 1.30 units 
      and mean duration of diabetes of 9.5 years. Fasting insulin (mean +/- SD: 15.1 
      +/- 10.6 mU/l) and fasting C-peptide (2.3 +/- 1.2 micrograms/l) were normal or 
      slightly elevated in all but one patient. Mean C-peptide increased from 2.3 +/- 
      1.2 micrograms/l to 3.5 +/- 2.2 micrograms/l (152% over basal) 6 minutes after 1 
      mg i.v. glucagon. In 15 patients the C-peptide response was greater than 130% of 
      basal. Islet cell cytoplasmic antibodies were detected in only two patients. The 
      distribution of HLA types was not significantly different from a control 
      population, with no increase in DR3 or DR4. Thus, absolute insulin deficiency is 
      uncommon in non-insulin dependent diabetics with 'secondary failure' of oral 
      hypoglycemic agents and such patients do not exhibit the immuno-genetic markers 
      of insulin-dependent diabetes.
FAU - Colman, P G
AU  - Colman PG
FAU - Harrison, L C
AU  - Harrison LC
FAU - Tait, B D
AU  - Tait BD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Aust N Z J Med
JT  - Australian and New Zealand journal of medicine
JID - 1264322
RN  - 0 (Autoantibodies)
RN  - 0 (Blood Glucose)
RN  - 0 (C-Peptide)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 9007-92-5 (Glucagon)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Autoantibodies/analysis
MH  - Blood Glucose/analysis
MH  - C-Peptide/blood
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/genetics/immunology
MH  - Female
MH  - Glucagon/pharmacology
MH  - HLA-DR Antigens
MH  - Histocompatibility Antigens Class II/*analysis
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Insulin/*metabolism
MH  - Insulin Secretion
MH  - Islets of Langerhans/immunology
MH  - Male
MH  - Middle Aged
EDAT- 1985/04/01 00:00
MHDA- 1985/04/01 00:01
CRDT- 1985/04/01 00:00
PHST- 1985/04/01 00:00 [pubmed]
PHST- 1985/04/01 00:01 [medline]
PHST- 1985/04/01 00:00 [entrez]
AID - 10.1111/j.1445-5994.1985.tb04008.x [doi]
PST - ppublish
SO  - Aust N Z J Med. 1985 Apr;15(2):209-12. doi: 10.1111/j.1445-5994.1985.tb04008.x.